CT-388 + Petrelintide by Roche: status and timeline

Milestones

Next · CT-388 + petrelintide Phase 2 ongoing

Roche and Zealand sign $5.3B co-dev agreementMar 2025Complete.
Petrelintide Phase 2 ZUPREME-1 meets primary endpointMar 2026Complete.
Petrelintide Phase 3 initiated2026Complete.
CT-388 + petrelintide Phase 2 ongoingTarget Apr 2026Current milestone.
Phase 3 combination studiesTarget 2027Not yet reached.

Most important updates

Petrelintide Phase 2 ZUPREME-1 trial meets primary endpoint for weight lossMar 2026

Upcoming

Apr 2026CT-388 + petrelintide Phase 2 ongoing (next)
2027Phase 3 combination studies

Current obstacles

Tolerability at higher dosesThe combination must balance weight loss benefit against nausea and other side effects seen with GLP-1 therapies.
Competitive obesity marketEli Lilly and Novo Nordisk dominate with established products (Zepbound, Ozempic). Roche must prove a clinical advantage.

Physics limits

Gastrointestinal effectsAll GLP-1/GIP agonists carry risk of nausea, vomiting and diarrhea, which limit dosing and patient adherence.
InjectabilityOnce-weekly injection dosing requires patient compliance and manufacturing supply chain for subcutaneous formulations.

How it works

3 parts

GLP-1/GIP

CT-388 dual hormone action

GLP-1 and GIP receptors boost insulin, cut appetite. Once weekly.

Amylin

Petrelintide pathway

Amylin receptors slow gastric emptying, reduce appetite via separate pathway.

Combination

Additive weight loss via dual pathways

Two appetite mechanisms may maximize loss with lower individual doses.

Spec sheet

Spec	CT-388 + Petrelintide
Administration	Once-weekly subcutaneous^R (reported)
ZUPREME-1 enrollment	493 patients^R (reported)

^R reported by the company

Update log

1 update

Mar 2026

Major: Petrelintide Phase 2 ZUPREME-1 trial meets primary endpoint for weight lossPressTest

About Roche

The team behind CT-388 + Petrelintide

Roche

Diagnostics, pharmaceuticals, obesity, sequencing

Swiss pharma giant (Basel, 1896) developing obesity drugs and sequencing systems. Acquired Carmot Therapeutics (2024) and partnered with Zealand Pharma for obesity treatments. Launched Axelios 1 (June 2026), a next-gen sequencing platform with same-day whole-genome analysis.

Obesity portfolio: CT-388 (once-weekly), CT-996 (daily oral), and petrelintide combo (Phase 3 by 2026).
Axelios 1 (June 2026): same-day whole genomes via SBX chemistry; first pharma sequencer vs Illumina.
SIX-listed, ~112,000 employees, established diagnostics and medicines across pharma.

roche.com (opens roche.com)Company profile →

Founded: 1896130 yrs
Headquarters: Switzerland
Status: Public
Valuation: public
Staff: ~112,000
Works in: BiotechGenomics & sequencing
Coverage: 2 programs · 4 updateslatest 29 Jun 2026checked 10 Oct
Partners: Zealand Pharma (opens zealandpharma.com)10x Genomics (opens 10xgenomics.com)
People: Thomas Schinecker (opens roche.com)Chief Executive Officer

Spec

CT-388 + Petrelintide

Administration

Once-weekly subcutaneous^R (reported)

ZUPREME-1 enrollment

493 patients^R (reported)